CYP17A1 and breast cancer: Hopper et al. [29] detected a deleterious CYP17A1 germline mutation, p.R239X, in three sisters with early-onset breast cancer, and the breast cancer risk associated with this mutation has been reported to be more than 20 times the population incidence.